BioXcel TherapeuticsBTAI 8 Shareholder Yield % is -130.26% as of Mar. 2026. GuruFocus rates BTAI with a GF Score™ of 8/100 and a GF Value™ of $0.67 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 970 Drug Manufacturers companies, BioXcel Therapeutics ranks worse than 98.14% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, BioXcel Therapeutics's Shareholder Yield % was -130.26%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
BioXcel Therapeutics Shareholder Yield % Related Terms
BioXcel Therapeutics Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for BioXcel Therapeutics's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BTAI vs IXHL, SCYX, INIS: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
BioXcel Therapeutics (BTAI) has a Shareholder Yield % of -130.26% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on BioXcel Therapeutics and its competitors. According to the industry distribution chart, BioXcel Therapeutics ranks #952 out of 970 companies in the Drug Manufacturers industry, placing it in the top 98.1%.
Is BioXcel Therapeutics' Shareholder Yield % too high?
BioXcel Therapeutics' current Shareholder Yield % is -130.26%. Based on the distribution chart, BioXcel Therapeutics ranks #952 out of 970 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, BioXcel Therapeutics has a GF Score™ of 8/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BioXcel Therapeutics' Shareholder Yield % compare to IXHL and SCYX?
According to the Drug Manufacturers industry distribution chart, BioXcel Therapeutics ranks #952 out of 970 companies for Shareholder Yield %. This places BioXcel Therapeutics in the lower half of its industry. The industry median Shareholder Yield % is 0.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.30, based on 970 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on BioXcel Therapeutics and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioXcel Therapeutics's current Shareholder Yield % is -130.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.67, compared to a current price of $1.38 — trading 106% above its estimated fair value. The current Shareholder Yield % is -130.26%. BioXcel Therapeutics' overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For BioXcel Therapeutics (BTAI), the current Shareholder Yield % is -130.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioXcel Therapeutics (BTAI) Overvalued in 2026?
Based on GuruFocus' analysis, BioXcel Therapeutics stock appears to be overvalued.
The current stock price of $1.38 is trading 106% above its estimated GF Value™ of $0.67.
GuruFocus considers BioXcel Therapeutics to be Significantly Overvalued.
Key valuation signals for BTAI:
Shareholder Yield %: -130.26%
GF Value™: $0.67 vs. price of $1.38 (106% above fair value)
No single metric tells the full story. See the BTAI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
8GF Score
Get the complete analysis for BTAI
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTAI has been successfully added to your 
